EMA Authorised: Anagrelide Viatris (previously Anagrelide Mylan) (anagrelide hydrochloride) — Viatris Limited

View source ↗

Summary

The EMA has authorised Viatris' Anagrelide (anagrelide hydrochloride) for the treatment of essential thrombocythemia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Essential Thrombocythemia

Drugs mentioned

• Anagrelide Viatris (anagrelide hydrochloride)

Snippet

Status: Authorised. Therapeutic area: Thrombocythemia, Essential. MAH: Viatris Limited. Decision date: 14/11/2025